AnaptysBio, Inc. (ANAB) Company Overview

What does AnaptysBio do after the First Tracks spin-off?

AnaptysBio, Inc. is now a biotechnology royalty-management company rather than the clinical-stage immunology developer that many readers still associate with the ANAB ticker. The company completed the separation of First Tracks Biotherapeutics on April 20, 2026, distributing one TRAX share for each ANAB share held on the April 6 record date. The retained AnaptysBio business manages the economics of two antibodies it originally discovered: Jemperli, commercialized by GSK, and imsidolimab, licensed to Vanda Pharmaceuticals. Its common stock remains listed on Nasdaq under ANAB.

A royalty manager, not a clinical-stage biotech

Before the spin-off, ANAB funded trials, manufacturing and a broad research organization. The retained company instead protects contract rights, oversees partner reporting, manages litigation and transition services, and allocates capital. Anaptys describes a virtual model with fewer than roughly ten contractor FTEs, annualized operating expenses below $10 million and an EBIT margin above 95%; these are management expectations, not yet a reported track record. The official post-spin company profile is therefore more relevant than older pipeline descriptions.

The retained assets and obligations

The separation is documented in AnaptysBio's April 20, 2026 Form 8-K. For researchers, the central lesson is that historical consolidated financial statements contain a business that no longer belongs inside ANAB's future operating model.

How does AnaptysBio make money?

AnaptysBio earns contractual economics rather than selling drugs. GSK and Vanda control development, manufacturing, regulation, pricing and commercialization. ANAB receives partner sales-based royalties plus milestone or transition-service revenue when conditions are met. The model removes most development and commercial cost, but also transfers operational control to partners.

Revenue mechanics

Why reported revenue is not the same as current cash

The most important accounting adjustment is the Jemperli royalty monetization. In 2021, ANAB received $250.0 million from Sagard and added another $50.0 million in 2024. In exchange, specified Jemperli royalties and milestones are paid to Sagard until cumulative receipts reach $600.0 million by March 31, 2031, or $675.0 million thereafter. ANAB still records royalty revenue as GSK sales occur, while the cash remittance reduces a nonrecourse royalty liability and the company recognizes imputed non-cash interest expense.

What do the latest reported results show?

The latest filed period, March 31, 2026, predates the April 20 separation and combines royalty management with First Tracks biopharma operations. Beginning in Q2, Anaptys expected historical First Tracks items to be presented as discontinued operations. The Q1 2026 Form 10-Q is therefore a bridge rather than a steady-state income statement.

Q1 2026 snapshot

Annual baseline and the milestone effect

Full-year 2025 collaboration revenue reached $234.6 million, compared with $91.3 million in 2024. The increase was not purely recurring growth: Jemperli generated $96.0 million of 2025 royalties, up 103%, while two one-time commercial sales milestones contributed $125.0 million after annual sales exceeded $1.0 billion. This difference is critical for normalized forecasting.

The official FY2025 results release provides the cleanest annual bridge, while the 2025 Form 10-K contains the full accounting and risk detail.

Which turning points created today's royalty model?

AnaptysBio's history matters because the current company is the monetization residue of two decades of antibody discovery. The strategic shift was not a single restructuring; it was a sequence of discovery, partnering, approval, financing and separation decisions that converted scientific assets into contractual cash-flow rights.

From antibody discovery to royalty stewardship

1. 2005
   AnaptysBio was founded in November. Its antibody-discovery platform created the scientific foundation for later partnered assets.
2. 2017
   The company completed its IPO on January 26, giving it public-market capital to advance internal and partnered immunology programs.
3. 2020–2021
   Jemperli regulatory filings and approvals generated major GSK milestones and proved that Anaptys-discovered antibodies could become commercial products.
4. 2021
   The $250.0M Sagard transaction monetized future Jemperli receipts, funding R&D but creating the central cash-timing obligation investors must model today.
5. 2024
   A $50.0M Sagard amendment expanded the monetization; Jemperli also began earning commercial sales milestones as adoption accelerated.
6. 2025
   Jemperli surpassed $1.0B in annual sales, producing $125.0M of sales milestones, while imsidolimab was licensed to Vanda for upfront consideration and a 10% royalty.
7. 2026
   First Tracks Biotherapeutics was spun off on April 20, leaving ANAB as a focused manager of royalty collaborations and capital returns.

The company's investor FAQ confirms its founding and IPO dates. The timeline explains why historical losses do not automatically imply weak post-spin economics, but also why the royalty stream is encumbered before cash reaches ANAB.

Why Jemperli economics define the company

Jemperli is the dominant asset because it already produces commercial royalties, has expanding oncology indications and sits on a royalty schedule that becomes more valuable as sales rise. AnaptysBio's official collaboration page reports annual worldwide net-sales rates of 8% up to $1.0 billion, 12% from $1.0 billion to $1.5 billion, 20% from $1.5 billion to $2.5 billion and 25% above $2.5 billion. The economic convexity is unusual: a dollar of sales at the top tiers contributes more royalty value than a dollar at the base tier.

Tiered royalty rates and patent duration

The same official partnership summary lists composition-of-matter patent expiries of 2035 in the United States, 2036 in Europe and 2037 in Japan, with possible extensions into 2038. Patent life is not a guarantee of market exclusivity or sales durability, but it sets the potential time horizon for royalty cash flows.

The Sagard paydown is the key timing bridge

The filing recorded a $240.8 million Jemperli royalty liability at March 31, 2026 after $32.6 million of Q1 payments to Sagard and $20.9 million of non-cash interest. Management's website projects the $600 million threshold could be reached as early as Q2 2027, but that projection assumes roughly 10% sequential quarterly Jemperli growth from Q4 2025 through Q2 2027 and certain EU milestones. A prudent model should treat that date as scenario-dependent rather than fixed.

What gives AnaptysBio a competitive advantage?

ANAB's advantage is not a sales force, manufacturing network or broad portfolio. It is ownership of contractual economics attached to assets that other companies fund and commercialize. This creates high potential operating leverage: once the transition is complete, incremental royalties should require little incremental operating expense. The company also has a substantial cash and investment position relative to its intended virtual cost base.

Asset quality versus concentration

The scorecard is an analytical interpretation based on the post-spin model, Q1 2026 liquidity and concentration disclosures; it is not a credit rating.

Competitive landscape

At the product level, Jemperli competes in a crowded PD-1/PD-L1 oncology market. The 10-Q specifically identifies Merck's Keytruda as a competing therapy and notes that pricing, reimbursement, clinical data, safety, guidelines and GSK's allocation of commercial resources can affect royalties. At the corporate level, ANAB also competes for investor attention with life-science royalty companies such as Royalty Pharma and XOMA Royalty, but its profile is far more concentrated.

Who owns AnaptysBio and how is it governed?

Ownership is concentrated. The 2025 Form 10-K/A, using information as of April 1, 2026 and related Schedule 13G filings, reported EcoR1 Capital at 27.1%, Point72 at 8.2% and BlackRock at 6.5%. Directors and officers as a group beneficially owned 36.9%, but that figure overlaps with EcoR1 because Oleg Nodelman sits on the board.

Ownership concentration

Governance after the separation

The 2025 Form 10-K/A describes a classified board divided into three classes. The board was reconfigured after four directors departed around the spin-off; Susannah Gray joined in March and Owen Hughes joined in May 2026. Their backgrounds are relevant: Gray is a former Royalty Pharma CFO, while Hughes leads XOMA Royalty. Chris Murphy became CFO in May 2026, and Daniel Faga continued as CEO under a consulting agreement expected to run at least through January 15, 2027.

Concentrated specialist ownership can support decisive capital allocation, but governance outcomes may be shaped by a few holders. Key issues are buyback execution, board independence, CEO succession and whether cash is returned or used for new royalty assets.

What opportunities could expand the royalty stream?

The opportunity set is concentrated but measurable. Jemperli sales growth, movement into higher royalty tiers, faster Sagard repayment, new indications and imsidolimab approval are the main value drivers. Unlike a diversified pharmaceutical company, ANAB does not need many successes; it needs its partners to execute well on a small number of high-impact events.

Jemperli expansion catalysts

AnaptysBio reports $1.128 billion of FY2025 Jemperli sales, 89% year-over-year growth, and $1.221 billion for the latest twelve months through Q1 2026. The company cites GSK peak monotherapy guidance of more than £2 billion, or approximately $2.7 billion, and estimates that level could imply more than $390 million of annualized royalties payable under the collaboration as early as 2029. These are partner and company expectations, not guaranteed outcomes, but they show why tier progression matters. The official Jemperli financial dashboard supplies the current sales context.

Imsidolimab optionality

Vanda's imsidolimab program provides a second asset. The FDA accepted the biologics license application for generalized pustular psoriasis and assigned a target action date of December 12, 2026. ANAB retains a 10% royalty on global net sales, while milestone rights were allocated to First Tracks under the separation agreement. Approval would not instantly create a large royalty stream: launch timing, physician adoption, reimbursement, competition and the addressable patient population would determine the ramp.

What risks could weaken AnaptysBio's outlook?

The retained company may be low-cost, but it is not low-risk. Its value depends on contract enforceability, partner behavior, product performance and the timing of cash rights. The narrower the operating platform becomes, the more each adverse event matters.

Product and partner concentration

The Q1 2026 filing says substantially all revenue is derived from GSK's commercialization of Jemperli. ANAB does not control GSK's marketing budget, trial priorities, pricing, regulatory strategy or portfolio allocation. Competition from Keytruda and other checkpoint inhibitors, changes in treatment guidelines, adverse safety findings, reimbursement pressure or weak adoption in new indications could reduce sales and delay movement through higher royalty tiers.

Accounting, legal and execution risks

Balance-sheet interpretation also requires care. At March 31, 2026, ANAB reported $286.5 million of cash and investments, $41.7 million of current liabilities, $263.7 million of liabilities related to future royalty sales and only $12.7 million of book equity. The royalty liability is nonrecourse and economically different from ordinary bank debt, but it represents a real claim on near-term royalty cash. The company also had 29.0 million shares outstanding at quarter-end and 29.1 million by May 7, so option exercises and equity awards can offset some repurchase benefits.

What matters most for valuation and the final takeaway?

ANAB is best approached with a sum-of-the-parts cash-flow model. Forecast Jemperli global sales, apply the tiered royalty schedule, separate milestones from recurring royalties, direct cash to Sagard until the cap is reached, and deduct post-spin costs and taxes. Imsidolimab remains probability-weighted optionality until approval and launch evidence improve confidence.

DCF drivers

The May 2026 business update is the freshest management summary, but the next quarterly filing should be more informative because it will begin separating First Tracks as discontinued operations and test the promised cost profile.